Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624331 | 1.00 | KDM4E (0.58) | KDM4EPKMACKR3NAMPTIDO1 | |
| SCHEMBL1624328 | 1.00 | KDM4E (0.58) | KDM4EPKMACKR3NAMPTIDO1 | |
| SCHEMBL4013908 | 0.92 | ACKR3 (0.60) | KDM4EPKMACKR3NAMPTSMN1; SMN2 | |
| SCHEMBL4014855 | 0.92 | ACKR3 (0.60) | KDM4EPKMACKR3NAMPTSMN1; SMN2 | |
| SCHEMBL4013905 | 0.92 | ACKR3 (0.60) | KDM4EPKMACKR3NAMPTSMN1; SMN2 | |
| SCHEMBL6152939 | 0.91 | KDM4E (0.68) | KDM4EPKMEPHX1SMN1; SMN2GPR119 | |
| SCHEMBL13625750 | 0.89 | KDM4E (0.55) | KDM4EPKMACKR3NAMPTIDO1 | |
| SCHEMBL15392117 | 0.89 | KDM4E (0.55) | KDM4EPKMACKR3NAMPTIDO1 | |
| SCHEMBL10272307 | 0.89 | KDM4E (0.55) | KDM4EPKMACKR3NAMPTIDO1 | |
| SCHEMBL14365880 | 0.86 | KDM4E (0.53) | KDM4EPKMACKR3NAMPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | KDM4E 610/4885PKM 1146/4885ACKR3 4431/4885 |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | KDM4E 2570/4885PKM 3059/4885ACKR3 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.